

Medical Policy

| Vimizim (elosulfase alfa) | |
|---------------------------------------|--|
| MEDICAL POLICY NUMBER | Med_Clin_Ops-061 |
| CURRENT VERSION EFFECTIVE DATE | January 1, 2024 |
| APPLICABLE PRODUCT AND MARKET | Individual Family Plan: All Plans Small Group: All Plans Medicare Advantage: All Plans |

Brand New Day/Central Health Medicare Plan develops policies and makes coverage determinations using credible scientific evidence including but not limited to MCG™ Health Guidelines, the ASAM Criteria™, and other third party sources, such as peer-reviewed medical literature generally recognized by the relevant medical community, physician specialty society recommendations, and expert opinion as relevant to supplement those sources. Brand New Day/Central Health Medicare Plan Medical Policies, MCG™ Guidelines, and the ASAM Criteria™ are not intended to be used without the independent clinical judgment of a qualified health care provider considering the individual circumstances of each member's case. The treating health care providers are solely responsible for diagnosis, treatment, and medical advice. Members may contact Brand New Day/Central Health Medicare Plan Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Brand New Day/Central Health Medicare Plan Medical Policy may contact the Health Plan. Brand New Day/Central Health Medicare Plan policies and practices are compliant with federal and state requirements, including mental health parity laws.

If there is a difference between this policy and the member specific plan document, the member benefit plan document will govern. For Medicare Advantage members, Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), govern. Refer to the CMS website at <http://www.cms.gov> for additional information.

Brand New Day/Central Health Medicare Plan medical policies address technology assessment of new and emerging treatments, devices, drugs, etc. They are developed to assist in administering plan benefits and do not constitute an offer of coverage nor medical advice. Brand New Day/Central Health Medicare Plan medical policies contain only a partial, general description of plan or program benefits and do not constitute a contract. Brand New Day/Central Health Medicare Plan does not provide health care services and, therefore, cannot guarantee any results or outcomes. Treating providers are solely responsible for medical advice and treatment of members. Our medical policies are updated based on changes in the evidence and healthcare coding and therefore are subject to change without notice. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). MCG™ and Care Guidelines® are trademarks of MCG Health, LLC (MCG).

PURPOSE

To promote consistency between reviewers in clinical coverage decision-making by providing the criteria that generally determine the medical necessity of Vimizim (elosulfase alfa) therapy.

POLICY/CRITERIA

Prior Authorization and Medical Review is required.

Coverage for Vimizim will be provided for 12 months and may be renewed.

Initial Therapy

1. Patient has a diagnosis of Mucopolysaccharidosis Type IVA (Morquio A Syndrome) confirmed by **one** of the following:
 - a. Absence or deficiency of fibroblast or leukocyte Galactosamine (N-Acetyl)-6-Sulfatase (GALNS) enzyme activity; **OR**
 - b. Molecular genetic testing for mutations in the GALNS gene; **AND**

Vimizim

Med_Clin_Ops_061

Medical Policy

2. Patient is displaying signs and symptoms of the disease e.g., kyphoscoliosis, genu valgum, pectus carinatum, gait disturbance, growth deficiency, etc.); **AND**
3. Vimizim is prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders.

Continuation Therapy

1. Patient has experienced a positive clinical response to elosulfase alfa therapy (e.g., improved endurance, improved functional capacity, reduced urine keratan sulfate excretion).

LIMITATIONS/EXCLUSIONS

1. Any indication other than those listed above due to insufficient evidence of therapeutic value

BACKGROUND

Mucopolysaccharidoses comprise a group of lysosomal storage disorders caused by the deficiency of specific lysosomal enzymes required for the catabolism of glycosaminoglycans (GAG). Mucopolysaccharidosis IVA (MPS IVA, Morquio A Syndrome) is characterized by the absence or marked reduction in N-acetylgalactosamine-6-sulfatase activity. The sulfatase activity deficiency results in the accumulation of the GAG substrates, KS and C6S, in the lysosomal compartment of cells throughout the body. The accumulation leads to widespread cellular, tissue, and organ dysfunction. Vimizim (elosulfase alfa) is intended to provide the exogenous enzyme N-acetylgalactosamine-6-sulfatase that will be taken up into the lysosomes and increase the catabolism of the GAGs KS and C6S. Elosulfase alfa uptake by cells into lysosomes is mediated by the binding of mannose-6-phosphate-terminated oligosaccharide chains of elosulfase alfa to mannose-6-phosphate receptors.

DEFINITIONS

1. VIMIZIM (elosulfase alfa) injection, for intravenous use. Initial U.S. Approval: 2014
 - a. Vimizim is supplied as a concentrated solution for infusion (1 mg per mL) requiring dilution. One vial of 5 mL contains 5 mg Vimizim.

CODING

| Applicable NDC Codes | |
|----------------------|-------------------------------------|
| 68135-0100-xx | Vimizim 1mg/1ml, 5ml vial injection |

| Applicable Procedure Code | |
|---------------------------|--|
| J1322 | Vimizim 5 mg injection; 1 billable unit = 1 mg |

| Applicable ICD-10 Codes | |
|-------------------------|---------------------------------|
| E76.210 | Morquio A mucopolysaccharidoses |

Vimizim

Medical Policy

EVIDENCE BASED REFERENCES

1. Vimizim® injection for intravenous use [prescribing information]. Novato, CA: BioMarin Pharmaceuticals; December 2019.
2. Hendriksz CJ, Berger KI, Giugliani R, et al. International guidelines for the management and treatment of Morquio A syndrome. *Am J Med Genet A*. 2015;167A:11-25.
3. Tomatsu S, Yasuda E, Patel P, et al. Morquio A syndrome: Diagnosis and current and future therapies. *Pediatr Endocrinol Rev*. 2014;12:141-151.
4. Regier DS, Tanpaiboon P. Role of elosulfase alfa in mucopolysaccharidosis IVA. *Appl Clin Genet*. 2016;9:67-74.

POLICY HISTORY

| | |
|-------------------------|---|
| Original Effective Date | May 24, 2021 |
| Revised Date | November 1, 2021: Annual review – no changes made. February 22, 2022: Annual review – no changes made. February 28, 2023 – Annual Review and approval (no policy revisions made) March 1, 2023 – Adopted by MA UM Committee (no policy revisions made) |

Approved by Pharmacy and Therapeutics 2/28/23